Dihydrofolate reductase inhibitors is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome.
This page is not an article and does not require a rating on the quality scale.
These agents inhibit the enzyme dihydrofolate reductase, an important rate-limiting step in the de novo folate synthesis pathway. Methotrexate is a cancer chemotherapeutic agent, whilst trimethoprim is an antibiotic. The reason for this disparity, despite both being dihydrofolate reductase inhibitors, is that methotrexate has a selective affinity for mammalian dihydrofolate reductase, while trimethoprim has a selective affinity for the bacterial enzyme.
Pages in category "Dihydrofolate reductase inhibitors"
There are 5 pages in this section of this category.
Top